Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

IVF debate: does less stimulation mean better embryos?

NCT ID NCT04983173

Knowledge-focused Sponsor: Fundación Santiago Dexeus Font Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study looked at 110 women aged 35-40 with low ovarian reserve undergoing IVF. Half received a mild stimulation (clomiphene plus low-dose hormones) and half received a stronger stimulation (higher-dose hormones). The goal was to see which approach led to more good-quality blastocysts. Researchers also tracked hormone changes and egg counts to understand how stimulation intensity affects early embryo development.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Clomiphene citrate and recombinant follicle-stimulating hormone (rFSH)
What this could lead to
If successful, this could help doctors choose the best stimulation intensity for IVF patients with low ovarian reserve, potentially improving embryo quality.
What could go wrong
This is a small, completed Phase 4 trial with only 110 participants. Results may not apply to all infertility patients, and the study focuses on embryo quality, not live birth rates.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

110 people

The number who actually took part.

Started

Nov 2021

Finished

Mar 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

35 to 40 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Able and willing to sign the Patient Consent Form and adhere to study visitation schedule * Antral follicle count (AFC) ≥ 5 and ≤ 10 * Anti-Mullerian hormone (AMH) ≤1.5 ng/ml (AMH result of up to one year will be valid) * Age ≥ 35 years and ≤40 years * BMI ≥18.5 and \<25 kg/m2 Exclusion Criteria: * AFC \>10 * History of untreated autoimmune, endocrine or metabolic disorders * Contraindication for hormonal treatment * Preimplantation genetic diagnosis cycles * Severe male factor (sperm concentration \<5 M/mL) * Recent history of severe disease requiring regular treatment (clinically significant concurrent medical condition that could compromise subject safety or interfered with the trial assessment and patients with any contraindication of being pregnant).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Infertility are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

infertility disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Infertility

Contacts and locations

Locations

  • Salud de la Mujer Dexeus

    Barcelona, 08028, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.